

CATABASIS PHARMACEUTICALS INC
Form 8-K
April 17, 2018

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **April 13, 2018**

Catabasis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-37467
(Commission
File Number)

26-3687168
(IRS Employer
Identification No.)

One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, Massachusetts
(Address of Principal Executive Offices)

02139
(Zip Code)

Registrant's telephone number, including area code: **(617) 349-1971**

Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.05 Costs Associated with Exit or Disposal Activities.

On April 13, 2018, the Board of Directors of Catabasis Pharmaceuticals, Inc. (the Company) committed to reduce the Company's workforce by approximately 42%, to a total of approximately 21 employees, as part of a corporate restructuring to focus resources on the Company's lead program, edasalonexent for the treatment of Duchenne muscular dystrophy. The Company expects the restructuring to result in approximately \$3.3 million in reduced annualized workforce expenses once the plan is fully implemented. The Company currently estimates that it will incur charges for one-time termination benefits in connection with this corporate restructuring of approximately \$1.0 million for employee severance, benefits and related costs in the second quarter of 2018, all of which are expected to result in cash expenditures. The Company expects to complete the reduction in workforce by the end of the second quarter of 2018.

Item 8.01 Other Events.

On April 17, 2018, the Company issued a press release announcing its commitment to a corporate restructuring. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.

On April 17, 2018, the Company is making publicly available on its website a corporate slide presentation with an updated slide regarding the Company's development pipeline. The updated slide is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	<u>Press release issued by the Company on April 17, 2018</u>
99.2	<u>Development pipeline summary</u>

Cautionary Note on Forward-Looking Statements

Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 8-K

Any statements in this Current Report on Form 8-K about future expectations, plans and prospects for the Company, including statements about the expected cost of the Company's strategic restructuring, the Company's expected future savings from the restructuring, the timing and completion of the restructuring and other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, project, target, potential, will, would, could, should, continue, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties regarding whether the Company will be able to implement the restructuring in a timely fashion and at the level of expense projected, whether the Company will be able to effectively manage the organizational changes brought about by the restructuring and have sufficient capital resources to fund its continuing operations in future periods to realize its anticipated cost savings, and other factors discussed in the Risk Factors section of the Company's annual report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATABASIS PHARMACEUTICALS, INC.

Date: April 17, 2018

By: */s/ Deirdre A. Cunnane*
Deirdre A. Cunnane
Chief Legal Officer